Azenosertib (also known as ZN-c3 clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER
This study is testing a new combination of medicines for people with bowel cancer that has spread. We want to see if a new drug called Azenosertib, given with two existing drugs (Encafenib and Cetuximab), is safe and helps shrink the cancer. This is an early-stage study.
For: metastatic colorectal cancerPoland · Spain · Germany - Authorised (with conditions)Human Pharmacology (Phase I)- Other
PHASE Ib STUDY WITH THE COMBINATION OF LB−100 (PP2A INHIBITOR) AND AZENOSERTIB (WEE1 INHIBITOR) IN PATIENTS WITH METASTATIC COLORECTAL CANCER The COLLEE trial
This study is called COLLEE and is looking at two new medicines, LB-100 and azenosertib, for people with bowel cancer that has spread. We want to see if this combination is safe and how well it works to treat the cancer.
For: Metastatic colorectal cancerNetherlands - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib and ZN-c3 Monotherapy in Subjects with Platinum-resistant Ovarian Cancer.
This study is testing different ways to use a new drug called azenosertib (also known as ZN-c3) for women with ovarian cancer that has become resistant to common treatments. It aims to find the safest and most effective dose, whether used alone or with another drug called niraparib.
For: Platinum-Resistant Ovarian CanceFrance